Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings

Bispecific antibodies (BsAbs) are novel antitumor agents that simultaneously engage tumor‐associated antigens with CD3 on endogenous effector T cells, leading to cancer cell death. The immune‐mediated toxicity rates associated with BsAbs are considerably lower than those seen with CAR T‐cell therapy. Hence, widespread utilization of BsAb products in outpatient and community settings will allow greater and more homogeneous access and thus improve patient outcomes. In this review, we discuss the unique toxicities associated with BsAbs currently approved by the U.S. Food and Drug Administration and provide a disease‐agnostic framework for the safe community administration of BsAb therapy. With academic, community, and industrial partnerships, broader deployment of BsAbs could be streamlined. Education, provision of in‐services, leveraging protocols and experiences, and development of templates and guidelines will make this transition smoother and allow every patient in need of BsAbs to receive timely access to these survival‐prolonging therapies.